Josephine Rini

Josephine Rini

Auto-generated profile, based on publicly available information

Josephine Rini

Division of Nuclear Medicine (C.C., J.R.), Department of Radiology, New York University School of Medicine, New York, New York

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2023 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
JRJ.N. Rini
J.N. Rini
GKG. Keir
G. Keir
CCC. Caravella
C. Caravella
AGA. Goenka
A. Goenka
AFA.M. Franceschi
A.M. Franceschi
BACKGROUND AND PURPOSE: Due to its high sensitivity, somatostatin receptor–PET may detect smaller lesions and more extensive disease than contrast-enhanced MR imaging, while the superior spatial resolution of MR imaging enables lesions to be accurately localized. We compared results of somatostatin receptor–PET/MRI with those of MR imaging alone and assessed the added value of vertex-to-thigh imaging for head and neck neuroendocrine tumors. MATERIALS AND METHODS: Somatostatin receptor–PET/CT was acquired as limited brain or head and neck imaging, with optional vertex-to-thigh imaging, following administration of 64CU/68GA DOTATATE. Somatostatin receptor–PET was fused with separately acquired contrast-enhanced MR imaging. DOTATATE activity was classified as comparable, more extensive, and/or showing additional lesions compared with MR imaging. Vertex-to-thigh findings were classified as positive or negative for metastatic disease or incidental. RESULTS: Thirty patients (with 13 meningiomas, 11 paragangliomas, 1 metastatic papillary thyroid carcinoma, 1 middle ear neuroendocrine adenoma, 1 external auditory canal mass, 1 pituitary carcinoma, 1 olfactory neuroblastoma, 1 orbital mass) were imaged. Five had no evidence of somatostatin receptor–positive lesions and were excluded. In 11/25, somatostatin receptor–PET/MRI and MR imaging were comparable. In 7/25, somatostatin receptor–PET/MRI showed more extensive disease, while in 9/25, somatostatin receptor–PET/MRI identified additional lesions. On vertex-to-thigh imaging, 1 of 17 patients was positive for metastatic disease, 8 of 17 were negative, and 8 of 17 demonstrated incidental findings. CONCLUSIONS: Somatostatin receptor–PET detected additional lesions and more extensive disease than contrast-enhanced MR imaging alone, while vertex-to-thigh imaging showed a low incidence of metastatic disease. Somatostatin receptor–PET/MRI enabled superior anatomic delineation of tumor burden, while any discrepancies were readily addressed. Somatostatin receptor–PET/MRI has the potential to play an important role in presurgical and radiation therapy planning of head and neck neuroendocrine tumors.

18 September 2025 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
AVAkarsh Vijayashankar
Akarsh Vijayashankar
GKGraham Keir
Graham Keir
MSMatthew Sagnelli
Matthew Sagnelli
DPDavid Petrover
David Petrover
MDMehdi Djekidel
Mehdi Djekidel
AFAna M. Franceschi
Ana M. Franceschi
BACKGROUND AND PURPOSE: The objectives for amyloid brain PET/CT and PET/MRI fusion images are to determine the agreement between visual interpretations of amyloid PET and to compare the results of visual interpretation with quantitative analysis as measured by the Centiloid (CL) scale. MATERIALS AND METHODS: One hundred sixty-seven clinical amyloid brain PET/CT scans were reviewed by 3 readers blinded to the original reports. Readers interpreted the amyloid PET scans as negative (0), positive (1), or indeterminate (2) for amyloid deposition. For quantitative analysis, 2 additional readers analyzed amyloid PET images using MIMNeuro to generate CL scores and regional standardized uptake ratios. Reader agreement was determined for visual and quantitative assessment. Using positive scan cutoffs of CL ≥ 40, we determined visual assessment-versus-quantitative assessment for scans consistently interpreted as positive by all 3 readers and for each reader. RESULTS: Fifty-three scans (31.74%) were rated amyloid-positive by all readers, while 62 scans (37.13%) were rated as amyloid-negative by all readers. The remaining 52 scans had inconsistent ratings with an agreement rate of 69.46%. Most (99/167; 59.28%) scans had CL scores above the CL-positive cutoff (CL ≥ 40), and 47/167 (28.14%) were CL-negative scans (CL <10). The lowest CL score to achieve visual positivity among all 3 readers was 57, while the lowest CL score to receive at least 1 indeterminate score was 11. The readers had a high degree of interreader reliability when rating scans as either positive (κ = 0.62) or negative (κ = 0.66) but were inconsistent when rating scans as indeterminate (κ = 0.17). Optimal cut-points were CL <3.6 for consistent negative and CL ≥28.8 for consistent visual positivity. CONCLUSIONS: Given the emergence of antiamyloid monoclonal therapies for early-stage Alzheimer disease, reliable detection of amyloidosis is critical for patient care. This study suggests that visual reads of amyloid PET may be insensitive when amyloidosis is milder but are spread across multiple regions (CL ranging from 40 to 59). Quantification of amyloid PET using the CL scale may help guide treatment of patients with mild amyloidosis who are under consideration for antiamyloid disease-modifying therapeutics.

25 April 2024 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
GKGraham Keir
Graham Keir
FMFaizullah Mashriqi
Faizullah Mashriqi
CCChristopher Caravella
Christopher Caravella
SCSean Clouston
Sean Clouston
JRJosephine N. Rini
Josephine N. Rini
AFAna M. Franceschi
Ana M. Franceschi
BACKGROUND AND PURPOSE: Fluorine 18-fluoro-L-dopa ([18F]-FDOPA) was approved by the FDA in 2019 and reimbursed by the Centers for Medicare & Medicaid Services in 2022 for use with PET to visualize dopaminergic nerve terminals in the striatum for evaluation of parkinsonism. We sought to determine the optimal image acquisition time for [18F]-FDOPA PET by evaluating rater-estimated FDOPA positivity and image quality across 4 time points. MATERIALS AND METHODS: Brain PET/CT was acquired 90 minutes following injection of 185 megabecquerel (5 mCi) of [18F]-FDOPA. PET was acquired in list mode for 20 minutes, and data were replayed to represent 15-, 10-, and 5-minute acquisitions. By means of MIMneuro, PET/MR imaging or PET/CT was independently graded for FDOPA positivity and image quality by 2 readers, blinded to the clinical report and diagnosis. Expert neuroradiologist clinical reads were used as the criterion standard. RESULTS: Twenty patients were included, average age 65.6 years, 55% women. Image-quality ratings decreased with shorter acquisition times for both readers (reader 1, ρ = 0.23, P = .044; reader 2, ρ = 0.24, P = .036), but there was no association between abnormality confidence scores and acquisition time (reader 1, ρ = –0.13, P = .250; reader 2, ρ = –0.19, P = .100). There was a high degree of consistency in intra- and interrater agreement and agreement with the expert reads when using acquisition times of ≥10 minutes (maximal confidence score consistency [ρ = 0.92] and interrater agreement [κ = 0.90] were observed at 15 minutes), while image quality was consistently rated as low and FDOPA positivity ratings were inconsistent when using a 5-minute acquisition time. CONCLUSIONS: Our study suggests that image-quality ratings were stable after 15 minutes and that between-subject abnormality detection rates were highly consistent between the 2 readers when acquired for at least 10 and up to 20 minutes but were inconsistent at 5 minutes. Shorter [18F]-FDOPA PET acquisition times may help maximize patient comfort while increasing throughput in the clinical setting.

18 September 2025 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
FMFaizullah Mashriqi
Faizullah Mashriqi
MCMichelle Chen
Michelle Chen
GKGraham Keir
Graham Keir
CCChris Caravella
Chris Caravella
AGAnuj Goenka
Anuj Goenka
AFAna M. Franceschi
Ana M. Franceschi
BACKGROUND AND PURPOSE: [18F]-fluoroestradiol (FES) is a novel molecular imaging radiopharmaceutical that has demonstrated promise in the staging of ER-positive brain metastases. Our aim was to determine if hybrid [18F] FES brain PET/MRI is superior to conventional brain MRI alone for detecting estrogen receptor (ER)–positive brain and calvarial metastases, compare limited [18F] FES brain PET with vertex-to-below the knees [18F] FES PET results, and determine the impact of [18F] FES brain PET/MRI on patient management decisions. MATERIALS AND METHODS: Following institutional review board approval, a retrospective analysis was conducted of patients who underwent [18F] FES brain PET/CT and contrast-enhanced brain MRI at our institution from January 2024 to November 2024. Intracranial lesions, including parenchymal, dural-based, calvarial, leptomeningeal, and extracranial soft tissue/scalp, were analyzed by an expert neuroradiologist using fused [18F] FES brain PET/MRI, and lesion size, location, and maximum standard uptake value were recorded. Two radiology residents reviewed separately acquired contrast-enhanced brain MRI reports and documented the number and location of intracranial lesions. A nuclear medicine physician reviewed vertex-to-below the knees [18F] FES PET/CT and reported the intracranial lesion number and maximum standard uptake value. RESULTS: Ten female patients with ER-positive breast cancer with 90 metastatic brain and calvarial lesions were included in our analysis. The mean age was 64.3 (SD, 7.5) years. Twelve of 90 (13.3%) lesions were occult on contrast-enhanced brain MRI but detected by 18F-FES brain PET/MRI, including 1 parenchymal lesion, 8/19 (42.1%) calvarial lesions, and 5/6 (50.0%) extracranial soft-tissue/scalp lesions. Meanwhile, 16/90 (17.8%) lesions were occult on vertex-to-thigh 18F-FES PET/CT compared with [18F] FES brain PET/MRI, including 13/58 (22.4%) parenchymal lesions and 3/7 (42.9%) dural-based lesions. There was a modification in patient management for 9 of 10 patients (90%) following the [18F] FES brain PET/MRI. CONCLUSIONS: By integrating [18F] FES brain PET/CT/MRI into our clinical workflow, we improved the detection of ER-positive lesions, resulting in a substantial impact on clinical management decisions.

1 May 2021 in JACC
Verified
Journal Article
Closed access
AMAmtul Mansoor
Amtul Mansoor
DCDavid Chang
David Chang
JGJames K. Gabriels
James K. Gabriels
JRJosephine Rini
Josephine Rini
KNKenneth Nichols
Kenneth Nichols
HIHaisam Ismail
Haisam Ismail